Showing 20 of 81 recruiting trials for “malt-lymphoma”
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
👨⚕️ Kerry A Rogers, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Nov 2024View details ↗
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingNCT06508684 ↗
Current Status of BTKi Treatment for CLL/SLL in China
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06796517 ↗
Immunotherapy in Lymphoma
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 73 sites📅 Started May 2024View details ↗
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
👨⚕️ Jianyong Li, PhD, MD, The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2024View details ↗
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
👨⚕️ Lugui Qiu, M.D., Ph.D., Hematology Hospital of the Chinese Academy of Medical Sciences📍 6 sites📅 Started Apr 2024View details ↗
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
👨⚕️ Andreas Engert, Prof., 1st Department of Medicine, Cologne Universit Hospital📍 1 site📅 Started Mar 2024View details ↗
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RecruitingNCT06151730 ↗
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →